Well you blithering idiots it has been
proven to work a long time ago. All your mentors and senior researchers
had to do was to tell you to create a protocol on this and get it
distributed to all 10 million yearly stroke survivors now and into the future. And they completely failed at their job, thus wasting all this time and money.
vagus nerve (59 posts to July 2012)
Vagus Nerve Stimulation Paired With Rehabilitation for Upper Limb Motor Impairment and Function After Chronic Ischemic Stroke: Subgroup Analysis of the Randomized, Blinded, Pivotal, VNS-REHAB Device Trial
Abstract
Background
Vagus
Nerve Stimulation (VNS) paired with rehabilitation improved upper
extremity impairment and function in a recent pivotal, randomized,
triple-blind, sham-controlled trial in people with chronic arm weakness
after stroke.
Objective
We aimed to determine whether treatment effects varied across candidate subgroups, such as younger age or less injury.
Methods
Participants
were randomized to receive rehabilitation paired with active VNS or
rehabilitation paired with sham stimulation (Control). The primary
outcome was the change in impairment measured by the Fugl–Meyer
Assessment Upper Extremity (FMA-UE) score on the first day after
completion of 6-weeks in-clinic therapy. We explored the effect of VNS
treatment by sex, age (≥62 years), time from stroke (>2 years),
severity (baseline FMA-UE score >34), paretic side of body, country
of enrollment (USA vs UK) and presence of cortical involvement of the
index infarction. We assessed whether there was any interaction with
treatment.
Findings
The primary outcome increased by 5.0 points (SD 4.4) in the VNS group and by 2.4 points (SD 3.8) in the Control group (P = .001,
between group difference 2.6, 95% CI 1.03-4.2). The between group
difference was similar across all subgroups and there were no
significant treatment interactions. There was no important difference in
rates of adverse events across subgroups.
Conclusion
The
response was similar across subgroups examined. The findings suggest
that the effects of paired VNS observed in the VNS-REHAB trial are
likely to be consistent in wide range of stroke survivors with moderate
to severe upper extremity impairment.
Introduction
Stroke
is a leading cause of adult disability. Upper limb impairment and
inability to effectively use the arm and hand for functional daily tasks
are common and persists in approximately half of people who have upper
limb impairment at onset.1
These limitations have a detrimental impact on quality of life and
improving upper limb impairment and function are a priority for stroke
survivors.2
The
use of vagus nerve stimulation (VNS) paired with rehabilitation to
improve moderate to severe upper limb motor deficits associated with
chronic ischemic stroke was recently approved the U.S. Food and Drug
Administration. VNS augments task specific neuroplasticity by providing
rapid cholinergic, noradrenergic, and serotonergic modulation.3
VNS paired with rehabilitation leads to greater recovery of forelimb
function in rodent models than either motor training or VNS alone.3,4 A combined analysis of data from 2 pilot feasibility trials of VNS paired with rehabilitation therapy5,6 found an improvement in impairment following VNS in people with long-term arm weakness after ischemic stroke.7
In the recently published pivotal VNS-REHAB trial, there was a
significant difference in change in Fugl–Meyer Assessment Upper
Extremity (FMA-UE) score in favor of paired VNS following 6 weeks of
in-clinic therapy.8
There was also a higher clinically important response rate, defined as a
greater than 6-point improvement in the FMA-UE score, and improvements
in functional measures with paired VNS at 90 days after completion of
in-clinic therapy. However, participants did not have a uniform response
to VNS, so identifying those with a higher chance of responding could
optimize prescription of this therapy. Pooled analysis of data from both
pilot trials did not find any clear relationship between baseline
variables and change in FMA-UE score with VNS, although lower baseline
Fugl–Meyer score was associated with greater improvement across both
treatment groups.7 However, this analysis was based on a small sample size.
Here
we perform a post-hoc subgroup analysis of data from the VNS-REHAB
trial. We identified variables of interest based on known predictors of
upper limb outcome. We examined whether the effect of paired VNS
treatment differs by reported sex, age, time from stroke, severity of
upper limb impairment, country of enrollment, paretic side, and whether
there was cortical involvement of the index infarction.
More at link.
No comments:
Post a Comment